27th Jul 2018 14:33
LONDON (Alliance News) - AstraZeneca PLC said Friday that the European Medicines Agency committee had recommended market authorisation for its lung cancer treatment.
The Committee for Medicinal Products for Human Use adopted a positive opinion on Imfinzi, the FTSE100-listed pharmaceutical company's treatment for non-small cell lung cancer.
This type of lung cancer it's the most common, with the American Cancer Society estimating that between 80% and 85% of all lung cancers are non-small cell.
AstraZeneca's treatment is intended to treat patients whose cancer is locally advanced - also known at Stage III cancer. Imfinzi is designed to stop tumour cells evading the patient's immune system.
"There have been no new treatments in this setting for decades. With approximately a third of European non-small cell lung cancer patients presenting with this stage of disease, we are excited by this potential new standard of care," said AstraZeneca Chief Medical Officer Sean Bohen.
Shares in AstraZeneca were down 0.3% at 5,778.00 pence on Friday.
Related Shares:
Astrazeneca